Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cabaletta Bio

1.99
+0.190010.56%
Post-market: 1.98-0.0107-0.54%19:50 EDT
Volume:4.57M
Turnover:8.63M
Market Cap:178.99M
PE:-0.78
High:2.00
Open:1.75
Low:1.70
Close:1.80
Loading ...

Cabaletta Bio Q4 Income From Operations USD -33.785 Million

THOMSON REUTERS
·
31 Mar

Cabaletta Bio Q4 Operating Expenses USD 33.785 Million

THOMSON REUTERS
·
31 Mar

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
31 Mar

Cabaletta Bio and Cellares complete TAP for rese-cel using Cell Shuttle

TIPRANKS
·
19 Mar

Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
17 Mar

Promising Clinical Advances and Strategic Developments Justify Buy Rating for Cabaletta Bio

TIPRANKS
·
19 Feb

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Feb

Cabaletta Bio’s Promising Clinical Progress and Strong Buy Rating by Douglas Tsao

TIPRANKS
·
19 Feb

BRIEF-Cabaletta Bio Announces Updated Clinical Data With Rese-Cel At February Scientific Meetings

Reuters
·
18 Feb

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications With Rese-Cel at February Scientific Meetings

THOMSON REUTERS
·
18 Feb

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

GlobeNewswire
·
18 Feb

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

GlobeNewswire
·
11 Feb

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

GlobeNewswire
·
29 Jan

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Jan

William Blair Remains a Buy on Cabaletta Bio (CABA)

TIPRANKS
·
14 Jan

BRIEF-Cabaletta Bio Outlines Strategic Priorities And Anticipated Key Milestones For 2025

Reuters
·
13 Jan

Cabaletta Bio Inc: Unaudited Cash and Cash Equivalents as of Dec 31, 2024 Was $164 Mln

THOMSON REUTERS
·
13 Jan

Cabaletta Bio : Expects Cash Position as of Dec 31, 2024, Will Enable It to Fund Its Updated Operating Plan Into First Half of 2026

THOMSON REUTERS
·
13 Jan

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

THOMSON REUTERS
·
13 Jan

Cabaletta Bio Inc - Caballetta to Meet FDA on Rese-Cel Trial Designs in 1H25

THOMSON REUTERS
·
13 Jan